Department of Medicine, Division of Endocrinology, The Lundquist Institute and Harbor-UCLA Medical Center, Torrance, California, USA.
Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Andrology. 2024 Oct;12(7):1547-1550. doi: 10.1111/andr.13724. Epub 2024 Aug 5.
This perspective provides an overview of issues needed to bring a testosterone-progestogen combined transdermal male hormonal contraceptive to the market. Large-scale phase 2b trials are near completion and a pivotal trial to confirm efficacy and safety has been designed. We believe we are close to accomplishing the steps necessary to bring the first male-directed effective, safe, and reversible pharmaceutical contraceptive approach to the public. If successful, we believe it will provide a new option for couples to consider in their family planning.
这篇观点文章概述了将睾酮-孕激素复方经皮男性荷尔蒙避孕药推向市场所需解决的问题。大型 2b 期临床试验即将完成，并且已经设计了一项关键性试验以确认疗效和安全性。我们相信，我们已经接近完成将首个男性定向的有效、安全和可逆的药物避孕方法推向公众所需的步骤。如果成功，我们相信它将为夫妇在计划生育方面提供一个新的选择。
